Skip to content
Home
Home
Case Files
October Term 2025
October Term 2024
October Term 2023
October Term 2022
October Term 2021
October Term 2020
Emergency Docket
Emergency Docket 2024-25
Emergency Docket 2023-24
Emergency Docket 2022-23
Petitions
Statistics
Newsfeed
Academic Round-up
Book reviews/Ask the author
Capital cases
Cases in the Pipeline
Emergency appeals and applications
Live
Merits Cases
SCOTUStalk
Special Features
About
Who We Are
Case Authors
Contact Us
Resources
Open X in a new tab
Open Bluesky in a new tab
Open TikTok in a new tab
Case Files
October Term 2025
October Term 2024
October Term 2023
October Term 2022
October Term 2021
October Term 2020
Emergency Docket
Emergency Docket 2024-25
Emergency Docket 2023-24
Emergency Docket 2022-23
Petitions
Statistics
Newsfeed
Academic Round-up
Book reviews/Ask the author
Capital cases
Cases in the Pipeline
Emergency appeals and applications
Live
Merits Cases
SCOTUStalk
Special Features
About
Who We Are
Case Authors
Contact Us
Resources
Kevin Noonan
,
Kevin E. Noonan is a partner with McDonnell Boehnen Hulbert & Berghoff LLP.
An antidote to the politics of the human gene patenting debate
Kevin Noonan
February 6, 2013
Previous
←
1
Next
→
